Renin-Angiotensin System Dysregulation: ADAM17 Activation Consequences Related to SARS-CoV-2

Julien      Giacomoni; Jean-Marc      Sabatier

doi:10.2174/0118715265299597240422102455

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

[1]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II type I receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules  2022; 27(7): 2048.
 [http://dx.doi.org/10.3390/molecules27072048] [PMID:  35408447]

[2]
Capuano C, De Federicis D, Ciuti D, et al. Impact of SARS-CoV-2 vaccination on FcγRIIIA/CD16 dynamics in natural killer cells: Relevance for antibody-dependent functions. Front Immunol  2023; 14: 1285203.
 [http://dx.doi.org/10.3389/fimmu.2023.1285203]

[3]
de Queiroz TM, Lakkappa N, Lazartigues E. ADAM17-mediated shedding of inflammatory cytokines in hypertension. Front Pharmacol  2020; 11: 1154.
 [http://dx.doi.org/10.3389/fphar.2020.01154] [PMID:  32848763]

[4]
Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood  2013; 121(18): 3599-608.
 [http://dx.doi.org/10.1182/blood-2012-04-425397] [PMID:  23487023]

[5]
Edwards D, Handsley M, Pennington C. The ADAM metalloproteinases. Mol Aspects Med  2008; 29(5): 258-89.
 [http://dx.doi.org/10.1016/j.mam.2008.08.001] [PMID:  18762209]

[6]
Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D’Souza SE. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem  2006; 281(6): 3157-64.
 [http://dx.doi.org/10.1074/jbc.M510797200] [PMID:  16332693]

[7]
Wang K, Xuan Z, Liu X, Zheng M, Yang C, Wang H. Immunomodulatory role of metalloproteinase ADAM17 in tumor development. Front Immunol  2022; 13: 1059376.
 [http://dx.doi.org/10.3389/fimmu.2022.1059376] [PMID:  36466812]

[8]
Gonçalves J, Santos CD, Fresco P, Fernandez-Llimos F. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. Rev Port Cardiol  2023; 42(4): 373-83.
 [http://dx.doi.org/10.1016/j.repc.2022.02.014] [PMID:  36893838]

[9]
Cao Z, Wu Y, Faucon E, Sabatier J-M. SARS-CoV-2 & COVID-19: Key-roles of the ‘renin-angiotensin’ system/vitamin D impacting drug and vaccine developments. Infect Disord Drug Targets  2020; 20(3): 348-9.
 [http://dx.doi.org/10.2174/1871526520999200505174704] [PMID:  32370727]

[10]
Leclerc PC, Proulx CD, Arguin G, et al. Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II. Am J Hypertens  2008; 21(1): 67-71.
 [http://dx.doi.org/10.1038/ajh.2007.1]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715265299597240422102455	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

Renin-Angiotensin System Dysregulation: ADAM17 Activation Consequences Related to SARS-CoV-2

Related Journals

Related Books